These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 18395492

  • 1. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S, Hughes TP, Mayrhofer G, Lyons AB.
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [Abstract] [Full Text] [Related]

  • 2. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.
    Cancer Res; 2006 Jan 01; 66(1):473-81. PubMed ID: 16397263
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
    Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M.
    Br J Haematol; 2009 Jan 01; 144(2):195-205. PubMed ID: 19016717
    [Abstract] [Full Text] [Related]

  • 4. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.
    Exp Hematol; 2009 Feb 01; 37(2):256-65. PubMed ID: 19056158
    [Abstract] [Full Text] [Related]

  • 5. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.
    Clin Sci (Lond); 2012 Jan 01; 122(1):13-24. PubMed ID: 21751967
    [Abstract] [Full Text] [Related]

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 01; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC, Seoane S, Ocaña A, Pandiella A.
    Clin Cancer Res; 2011 Sep 01; 17(17):5546-52. PubMed ID: 21670084
    [Abstract] [Full Text] [Related]

  • 11. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Leonard JT, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd K, Druker BJ, Tyner JW, Chang BH, Lind E.
    Blood; 2021 Feb 18; 137(7):939-944. PubMed ID: 32898857
    [Abstract] [Full Text] [Related]

  • 12. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
    Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC.
    J Med Chem; 2006 Nov 16; 49(23):6819-32. PubMed ID: 17154512
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dasatinib: BMS 354825.
    Drugs R D; 2006 Nov 16; 7(2):129-32. PubMed ID: 16542059
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S, Tauchi T, Ohyashiki K.
    Clin Cancer Res; 2008 Oct 01; 14(19):6181-6. PubMed ID: 18829496
    [Abstract] [Full Text] [Related]

  • 18. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
    Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.
    Cancer Res; 2007 Mar 15; 67(6):2800-8. PubMed ID: 17363602
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.
    J Thorac Cardiovasc Surg; 2013 Feb 15; 145(2):531-8. PubMed ID: 23142123
    [Abstract] [Full Text] [Related]

  • 20. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM, Saigal B, Talpaz M, Donato NJ.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.